Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation (Q31864785)

4 July 2017

Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation (English)

1 reference

4 July 2017

1 reference

M Fluker

1

1 reference

4 July 2017

J Grifo

2

1 reference

4 July 2017

A Leader

3

1 reference

4 July 2017

M Levy

4

1 reference

4 July 2017

D Meldrum

5

1 reference

4 July 2017

S J Muasher

6

1 reference

4 July 2017

J Rinehart

7

1 reference

4 July 2017

Z Rosenwaks

8

1 reference

4 July 2017

R T Scott

9

1 reference

4 July 2017

W Schoolcraft

10

1 reference

4 July 2017

D B Shapiro

11

1 reference

4 July 2017

North American Ganirelix Study Group

12

1 reference

4 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

4 July 2017

Fertility and Sterility

1 reference

4 July 2017

75

1 reference

4 July 2017

38-45

1 reference

4 July 2017

1

1 reference

GnRH analogues in ovarian stimulation

4 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901638-1

Induction of multiple follicular development for IVF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901638-1

Future trends in infertility treatment: challenges ahead

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901638-1

Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901638-1

Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901638-1

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901638-1

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901638-1

Neuropsychologic dysfunction in women following leuprolide acetate induction of hypoestrogenism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901638-1

The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901638-1

Assisted reproduction-in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin-releasing hormone analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2800%2901638-1

10.1016/S0015-0282(00)01638-1

7 January 2021

Identifiers

DOI

1 reference

4 July 2017

1 reference